Clinical applications of dosimetry for mIBG therapy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 2, 2011, Pages 116-125

  Flux, G D ^a   Chittenden, S J ^a   Saran, F ^a   Gaze, M N ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Diagnostic imaging; Neuroendocrine tumors; Palliative care; Pediatrics

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131;

BONE MARROW TOXICITY; CARCINOID; DOSIMETRY; ECHO PLANAR IMAGING; HUMAN; NEUROBLASTOMA; NEUTROPENIA; PARAGANGLIOMA; PATIENT SAFETY; PERSONALIZED MEDICINE; PHEOCHROMOCYTOMA; RADIATION ABSORPTION; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; RADIATION SAFETY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; TREATMENT PLANNING; TUMOR DOSIMETRY; WHOLE BODY DOSIMETRY;

3-IODOBENZYLGUANIDINE; ADULT; CHILD; HUMANS; IODINE RADIOISOTOPES; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 79957636978     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Wieland DM, Wu JI, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled Adrenergic Neuron-Blocking Agents - Adrenomedullary Imaging with [I-131]Iodobenzylguanidine. J Nucl Med 1980;21:349-53. (Pubitemid 10100562)
2. Wiseman GA, Pacak K, O'Dorisio MS, Neumann DR, Waxman AD, Mankoff DA et al. , Heiba SI, Serafini AN, Tumeh SS, Khutoryansky N, Jacobson AF. Usefulness of I-123-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial. J Nucl Med 2009;50:1448-54.
3. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. I-123-MIBG Scintigraphy and F-18-FDG PET in Neuroblastoma. J Nucl Med 2009;50:1237-43.
4. Hoefnagel CA, Voute PA, deKraker J, Jager FCAD, Taal BG, Engelsman EE. Side-Effects of I-131-Mibg Therapy of Neural Crest Tumors. Aust NZ J Med 1988;18:504.
5. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT et al. Phase I/II study of i-131 metaiodobenzylguanidine in chemoresistant neuroblastoma - a United-Kingdom Childrens Cancer study-group investigation. J Clin Oncol 1992;10:1889-96.
6. Troncone L, Rufini V, Danza FM, Donfrancesco A, Delaurentis C, Cozza R et al. Radioiodinated metaiodobenzylguanidine (I-Metaiodobenzylguanidine) scintigraphy in neuroblastoma - a review of 160 studies. J Nucl Med Allied S 1990;34:279-88.
7. Gedik GK, Hoefnagel CA, Bais E, Olmos RAV. I-131-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725-33.
8. Loh KC, Fitzgerald PA, Matthay KK, Yeo PPB, Price DC. The treatment of malignant metaiodobenzylguanidine 0-131-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20:648-58. (Pubitemid 28056835)
9. Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio C, Lanino E, Bertolazzi L et al. I-131-metaiodobenzylguanidine (1-131-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Brit J Cancer 1999;81:1378-84.
10. Nguyen C, Faraggi M, Giraudet AL, Labriolle-Vaylet C, Aparicio T, Rouzet F et al. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 2004;45:1660-8. (Pubitemid 47618472)
11. Castellani MR, Seregni E, Maccauro M, Chaise C, Aliberti G, Orunesu E et al. MIBG for diagnosis and therapy of medullary carcinoma: is there still a role ? Q J Nucl Meed Mol Im 2008;52:430-40
12. Lucignani G, Bombardieri E. Progress and challenges in neuroendocrine and neural crest tumours: molecular imaging and therapy. European J Nucl Med and Molecular Imaging 2009;36:2081-8.
13. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM procedure guidelines for I-131-meta-iodobenzylguanidine (I-131-mIBG) therapy. Eur J Nucl Med Mol Imaging 2008;35:1039-47.
14. Navalkissoor S, Alhashimi DM, Quigley AM, Caplin ME, Buscombe JR. Efficacy of using a standard activity of I-131-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37:904-12.
15. Sgouros G. Bone-marrow dosimetry for radioimmunotherapy - theoretical derivation of the red marrow to blood activity concentration ratio. J Nucl Med 1993;34:160.
16. Sisson JC, Hutchinson RJ, Carey JE, Shapiro B, Johnson JW, Mallette SA et al. Toxicity from Treatment of Neuro-Blastoma with I-131-Meta- Iodobenzylguanidine. Eur J Nucl Med 1988;14:337-40.
17. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma, treated with I-131-MIBG. J Nucl Med 2001;42:1713-21. (Pubitemid 33131334)
18. Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H. Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2010;37:1279-90.
19. Chittenden S, Pratt B, Pomeroy K, Black P, Long C, Smith N et al. Optimization of equipment and methodology for whole-body activity retention measurements in children undergoing targeted radionuclide therapy. Cancer Biother Radiopharm 2007;22:247-53.
20. Divoli A, Spinelli A, Chittenden S, Dearnaley D, Flux G. Whole-body dosimetry for targeted radionuclide therapy using spectral analysis. Cancer Biother Radiopharm 2005;20:66-71 (Pubitemid 40478524)
21. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Physics 2003;85:294-310. (Pubitemid 36999340)
22. Buckley SE, Chittenden SC, Saran FH, Meller ST, Flux GD. Whole-body dosimetry for individualized treatment planning of 131I-mIBG radionuclide therapy for neuroblastoma. J Nucl Med 2009;50:1518-24.
23. Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of I-131 Metaiodobenzylguanidine for Treatment of Resistant Neuroblastoma - Results of a UK Study. Eur J Nucl Med 1991;18:308-16.
24. Tristam M, Alaamer AS, Fleming JS, Lewington VJ, Zivanovic MA. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: Risk versus benefit. J Nucl Med 1996;37:1058-63. (Pubitemid 126447150)
25. Flux GD, Guy MJ, Papavasileiou P, South C, Chittenden SJ, Flower MA et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm 2003;18:81-7. (Pubitemid 36307469)
26. Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H. Patient dosimetry for I-131-MIBG therapy for neuroendocrine tumours based on I-123-MIBG scans. European J Nucl Med Mol Imaging 2002;29:1581-7.
27. Bolster AA, Hilditch TE, Wheldon TE, Gaze MN, Barrett A. Dosimetric Considerations in I-131 Mibg Therapy for Neuroblastoma in Children. Brit J Radiol 1995;68:481-90.
28. Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler RE et al. Treatment planning for internal radionuclide therapy - 3- Dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med 1990;31:1884-91. (Pubitemid 20374529)
29. Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D et al. Dosimetry for fractionated I-131-mIBG therapies in patients with primary resistant high-risk neuroblastoma: Preliminary results. Cancer Biother Radiopharm 2007;22:105-12.
30. Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, Kaminiski MS. Accurate dosimetry in I-131 radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med 2005;46:840-9.
31. Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Compton scatter compensation using the triple-energy window method for single-isotope and dual-isotope SPECT. J Nucl Med 1993;34:2216-21. (Pubitemid 24002970)
32. Koral KF, Huberty JP, Frame B, Matthay KK, Maris JM, Regan D et al. Hepatic absorbed radiation dosimetry during I-131 Metaiodobenzylguanadine (MIBG) therapy for refractory neuroblastoma. Eur J Nucl Med Mol Imaging 2008;35:2105-12.
33. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195-9. (Pubitemid 40696102)
34. De Jong M, Breeman WAP, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using Lu-177- and Y-90-Labeled somatostatin analogs. J Nucl Med 2005;46:13S-17S.
35. Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T et al. Potential increased tumor-dose delivery with combined I-131-MIBG and Y-90-DOTATOC treatment in neuroendocrine tumors: A theoretic model. J Nucl Med 2006;47:660-7. (Pubitemid 46768468)
36. Mairs RJ, Fullerton NE, Zalutsky MR, Boyd M. Targeted radiotherapy: Microgray doses and the bystander effect. Dose-Response 2007;5.
37. Wheldon TE, ODonoghue JA, Barrett A, Michalowski AS. The curability of tumors of differing size by targeted radiotherapy using I-131 or Y-90. Radiother Oncol 1991;21:91-9.
38. Mastrangelo R, Tornesello A, Lasorella A, Iavarone A, Mastrangelo S, Riccardi R et al. Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neuro-Oncol 1997;31:153-8. (Pubitemid 27077722)
39. McCluskey AG, Boyd M, Pimlott SL, Babich JW, Gaze MN, Mairs RJ. Experimental treatment of neuroblastoma using [I-131]metaiodobenzylguanidine and topotecan in combination. Brit J Radiol 2008;81:S28-S35
40. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm 2003;18:89-97. (Pubitemid 36307470)
41. Bodey RK, Evans PM, Flux GD. Spatial aspects of combined modality radiotherapy. Radiother Oncol 2005;77:301-9. (Pubitemid 41785341)
42. Boyd M, Sorensen A, McCluskey AG, Mairs RJ. Radiation quality-dependent bystander effects elicited by targeted radionuclides. J Pharm Pharmacol 2008;60:951-8.
43. Carlsson J, Hakansson E, Eriksson V, Grawe J, Wester K, Grusell E et al. Early effects of low dose-rate radiation on cultured tumor cells. Cancer Biother Radiopharm 2003;18:663-70. (Pubitemid 37082387)
44. Mairs RJ, Russell J, Cunningham S, ODonoghue JA, Gaze MN, Owens J et al. Enhanced tumor uptake and in-vitro radiotoxicity of no-carrier- added [I-131] metaiodobenzylguanidine - implications for the targeted radiotherapy of neuroblastoma. Eur J Cancer 1995;31A:576-81.
45. Coleman RE, Stubbs JB, Barrett JA, de la Guardia M, LaFrance N, Babich JW. Radiation dosimetry, pharmacokinetics, and safety of ultratrace (TM) iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. Cancer Biother Radiopharm 2009;24:469-75.
46. Popp M, Strumpf A, Zophel K, Stroszczynski C, Kotzerke J. Increased uptake of I-131-MIBG after intra-arterial application in liver metastases of a neuroendocrine tumor. Eur J Nucl Med Mol Imaging 2010;37:180.
47. Brogsitter C, Pinkert J, Bredow J, Kittner T, Kotzerke J. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of I-131-MIBG. J Nucl Med 2005;46:2112-6. (Pubitemid 46657461)
48. Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N et al. Local delivery of I-131-MIBG to treat peritoneal neuroblastoma. Eur J Nucl Med Mol Imaging 2003;30:1246-50.
49. Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V et al. Criteria for evaluation of disease extent by I-123- metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Brit J Cancer 2010;102:1319-26.
50. Ott RJ, Tait D, Flower MA, Babich JW, Lambrecht RM. Treatment planning for I-131 metaiodobenzylguanidine radiotherapy of neural crest tumors using I-124 metaiodobenzylguanidine positron emission tomography. Brit J Radiol 1992;65:787-91.
51. Gregory RA, Hooker CA, Partridge M, Flux GD. Optimization and assessment of quantitative I-124 imaging on a Philips Gemini dual GS PET/CT system. European J Nucl Med Mol Imag 2009;36:1037-48.
52. Watanabe S, Hanaoka H, Liang JX, Iida Y, Endo K, Ishioka NS. PET Imaging of Norepinephrine Transporter-Expressing Tumors Using Br-76- meta-Bromobenzylguanidine. J Nucl Med 2010;51:1472-9.
53. Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E et al. (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging 2010;54:100-13.